NP&PP department, psychedelics

How does 2C-B compare to psilocybin and placebo regarding subjective effects, mood and cognition?

2C-B is a hallucinogenic phenethylamine derived from mescaline. First made by the grand wizard of psychedelic biochemistry Sasha Shulgin in 1974, 2C-B became his favourite of the "magical-half dozen" of substituted phenethylamines. Published in his seminal book PIHKAL, 2C-B promptly reached the wider world of recreational users. However, despite being the most popular 2C-X compound… Continue reading How does 2C-B compare to psilocybin and placebo regarding subjective effects, mood and cognition?

Uncategorized

Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees

Historical and recent research suggests psychedelic drugs may be efficacious in alleviating anxiety-related symptoms among healthy and clinical populations. A recent study by our group investigated whether psilocybin-containing truffles, when taken in a supportive group setting, altered ratings of state and trait anxiety, and if these alterations were related to changes in neuroticism, mindfulness capacities,… Continue reading Decreases in State and Trait Anxiety Post-psilocybin: A Naturalistic, Observational Study Among Retreat Attendees

Event, NP&PP department, Psychedelic-Assisted Psychotherapy, psychedelics

Save the date – What do we mean by Psychedelic-Assisted Psychotherapy?

On September 28 uniMIND Central Session will host Mauro Cavarra for an open discussion on our recently published paper reviewing the different models of psychedelic-assisted psychotherapy used in clinical trials. The session will start at 7pm (CEST) and anyone is welcome to join via the MIND Community Platform.

microdosing, NP&PP department, pain, psychedelics, survey

Analgesic potential of psychedelics in chronic pain sufferers: a population survey

Do psychedelics work for chronic pain? We asked the patients themselves! In our recent article we present the results of a survey study addressed to chronic pain sufferers who are using psychedelics (both in full doses and in microdoses) to seek relief. Our results support the hypothesis that both dosing regimens hold promise for chronic… Continue reading Analgesic potential of psychedelics in chronic pain sufferers: a population survey